Why UTMD Stock surged +3.64% Today — RQD Quant Desk Flash

UTMD scores 62 out of 100, a letter grade of C, with the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine: 17 / 20. this pillar reflects ROIC of 26.9% and an FCF yield of 6.73%. This is the strongest pillar and suggests the business generates returns well above a typical cost of capital relative to the capital it employs, with a meaningful share of market value returned as free cash flow.
• Whale / 13F Flow: 6 / 20. this pillar measures institutional accumulation and options positioning. The low score indicates limited institutional-flow support in the source data, a factor that can leave a stock more sensitive to its own tape.
• Insider Conviction: 15 / 20. this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A moderately positive reading is consistent with the insider purchase headline in the news wire (see Recent Catalysts).
• Macro Regime Fit: 11 / 20. beta is 1.0 and the pillar reflects sector sensitivity. The score implies the stock tracks broad market swings without a clear defensive or cyclical edge.
• Forensic Balance Sheet: 13 / 20. the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. These figures sit in a middle band: not distressed, but not showing strong forensic scores.

Taken together, the rating points to a business with high capital efficiency and cash generation, offset by weak institutional flow and middling balance-sheet and macro-fit scores. For a prospective investor, the upside case rests on the cash-return profile; the valuation tradeoff is that an EV/EBITDA of 10.8 and a 6.73% FCF yield must be weighed against declining reported revenue in the SEC financials (see Financial Trend). The Hold verdict signals balanced rather than asymmetric risk-reward at the current price.

. (UTMD) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry, with a market capitalization of $0.2B. Per the market data, the company reports a gross margin of 57.1% and an operating margin of 29.6%.

Revenue declined from $50.2M (FY 2023) to $40.9M (FY 2024) and $38.5M (FY 2025), while operating income fell from $16.8M to $11.4M over the same span. Per the market data, net margin is 0%, and net income is reported as — in each period. ROIC is 26.9%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 4/9. Cash rose from $83.0M to $85.8M, and debt is listed as N/A in the reported periods.

• 🐂 Primary Bull Case: ROIC of 26.9% and a 6.73% FCF yield indicate a highly capital-efficient cash engine trading at 10.8x EV/EBITDA. With Fundamental Cash Engine at 17/20 (ROIC 26.9%, FCF yield 6.73%) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $53.66 – $76.89 52-week range.
• 🐻 Primary Bear Case: Revenue fell from $50.2M to $38.5M over two years and net margin is 0%, while institutional flow scores only 6 of 20. Investors must weigh current valuation and 10.8x EV/EBITDA against 29.6% operating margins and a 1.00 macro beta if sector demand softens.

Sector is Health Care and industry is Medical/Dental Instruments. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data. —

• Key Question #1: What is the current status and final terms of the tender offer referenced in the news wire, and how do the "corrected results" change the reported figures?
• Key Question #2: Why is net income reported as — and EPS as N/A across all periods, and what drives the 0% net margin against a 29.6% operating margin?
• Key Question #3: What are the reported debt figures, since debt is listed as N/A in every period?